BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is trading at $59.87, about ₹5,751 at today's USD/INR rate, as of 29 Sep 2026, 4:00 PM ET, up 0.69% today. Indian residents can buy BioMarin Pharmaceutical from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
$58.98
Today's high
$60.09
52 week low
$49.26
52 week high
$70.98
BMRN opened at $59.26, closed previously at $59.46, and has traded between $49.26 and $70.98 over the past 52 weeks.
About
BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique synthetic oral version of 6R-BH4, prescribed for phenylketonuria (PKU), an inherited metabolic condition. Further expanding its product portfolio, BioMarin provides Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme administered via subcutaneous injection to lower blood Phe levels. Also available are Brineura, a recombinant human tripeptidyl peptidase 1 used in treating ceroid lipofuscinosis type 2, a variant of Batten disease; Voxzogo, a daily injectable c-type natriuretic peptide analog for achondroplasia; and Aldurazyme, a refined protein mirroring the naturally occurring human enzyme alpha-L-iduronidase. Beyond its established products, BioMarin has a robust development pipeline. This includes valoctocogene roxaparvovec, an adeno-associated virus vector undergoing Phase III clinical trials for severe hemophilia A. Additionally, BMN 307, an AAV5-mediated gene therapy, is in Phase 1/2 trials, aiming to normalize blood phenylalanine levels in PKU patients, while BMN 255 is also in Phase 1/2 trials for primary hyperoxaluria. Its clientele spans specialty pharmacies, hospitals, international government health bodies, and a network of distributors and pharmaceutical wholesalers. These services reach patients and healthcare providers across the United States, Europe, Latin America, and other global markets. BioMarin maintains strategic licensing and collaborative alliances with partners such as Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. Established in 1996, the company's corporate headquarters are located in San Rafael, California.
Key statistics
Avg. volume
2.08M
Market cap
$11.57B
P/E Ratio
157.55
Price-to-sales ratio
3.40
Enterprise value
$10.73B
Free cash flow yield
6.36%
Debt-to-equity ratio
0.66
Return on equity
5.73%
ROIC
5.64%
Beta
0.24
Dividend yield
0.00%
Last dividend
$0.00
Financial overview
Revenue
$3.22B
Earnings per share
$1.82
Free cash flow
$724.96M
Net profit margin
2.14%
Gross margin
75.55%
EBITDA
$572.94M
Revenue growth
12.87%
Similar securities
This is not an investment recommendation
How to buy BioMarin Pharmaceutical from India
Indian residents can buy BioMarin Pharmaceutical shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.
Search for BioMarin Pharmaceutical and place an order
Find BioMarin Pharmaceutical by name or by its ticker, BMRN, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. BioMarin Pharmaceutical trades 7:00 pm – 1:30 am IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your BioMarin Pharmaceutical position in USD and INR. BioMarin Pharmaceutical pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in BioMarin Pharmaceutical from India
Trading and taxes when buying BioMarin Pharmaceutical from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm ET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneBioMarin Pharmaceutical does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
- US estate tax
- May applyUS-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons.US estate tax calculator
Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
FAQs
Can Indian residents buy BioMarin Pharmaceutical stock?
Yes. BioMarin Pharmaceutical (BMRN) has been listed on NASDAQ since 1999, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
How much does one BioMarin Pharmaceutical share cost in rupees?
One BioMarin Pharmaceutical share is $59.87 — about ₹5,751 at a USD/INR rate of 96.06 on 29 Sep 2026. Both the BioMarin Pharmaceutical price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying BioMarin Pharmaceutical from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
Can I buy whole shares of BioMarin Pharmaceutical?
Yes. One BioMarin Pharmaceutical share is $59.87, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in BioMarin Pharmaceutical.
How are gains on BioMarin Pharmaceutical shares taxed in India?
The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the BioMarin Pharmaceutical price. Paasa issues a capital-gains statement for your return.
Does BioMarin Pharmaceutical pay a dividend?
No. BioMarin Pharmaceutical does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade BioMarin Pharmaceutical from India?
NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.
Is there estate or inheritance tax on BioMarin Pharmaceutical shares held from India?
US-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons. It applies to your overall holdings in that jurisdiction rather than to any one position. Paasa's US estate tax calculator shows the exposure for a given portfolio value.
Do I have to declare BioMarin Pharmaceutical shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your BioMarin Pharmaceutical holding, its cost and its closing value.
How do I sell BioMarin Pharmaceutical and bring the money back to India?
You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.